成人胶质母细胞瘤:SNO与EANO共识综述
该共识综述由SNO与EANO更新,讨论成人胶质母细胞瘤当前管理。2021年WHO中枢神经系统肿瘤分类将胶质母细胞瘤限定为IDH野生型,有助于预后判断和优化治疗,并使临床试验入组人群更均一。综述还回顾免疫治疗、病毒治疗、靶向分子治疗、诊疗一体化及抗体偶联药物等新疗法,以及研究挑战与未来方向。
要点
- 胶质母细胞瘤为最常见的恶性原发性脑肿瘤,致死致残率高。
- 2021年WHO分类将胶质母细胞瘤限定为IDH野生型肿瘤。
- 共识综述涵盖当前管理及免疫、病毒、靶向等新疗法。
核心结论
- 2021年WHO分类将胶质母细胞瘤限定为IDH野生型,改善了对这些肿瘤预后和最佳治疗的理解。
研究设计与样本
- 由神经肿瘤学会(SNO)与欧洲神经肿瘤协会(EANO)发布的更新共识综述。
主要发现
- 胶质母细胞瘤是最常见的恶性原发性脑肿瘤,也是发病和死亡的主要原因。
- 2021年WHO分类更新使临床试验可入组更均一的患者人群,便于评估新疗法。
临床怎么用
- 综述讨论了胶质母细胞瘤患者的当前管理。
- 综述回顾了免疫治疗、病毒治疗、靶向分子治疗、诊疗一体化及抗体偶联药物等新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody-drug conjugates will be reviewed, as well as the current challenges and future directions for research.
引用
- Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2025. PMID: 40827022. doi:10.1093/neuonc/noaf177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。